NASDAQ$RXRX
Recursion Pharmaceuticals Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported business updates and financial results for the third quarter ending September 30, 2024.
Recursion Pharmaceuticals reported its Q3 2024 financial results, with a focus on the anticipated closing of the business combination with Exscientia. The company highlighted multiple clinical trial milestones and an expanded collaboration with Google Cloud. Total revenue increased to $26.1 million, driven by the Roche & Genentech partnership and a $30 million acceptance fee for a neuroscience phenomap.
- Multiple clinical trial milestones were achieved, including Phase 2 data for CCM and first patient dosed for C. difficile infection Phase 2 trial.
- First neuroscience phenomap was optioned by Roche-Genentech for $30 million, potentially exceeding $500 million.
- Expanded collaboration with Google Cloud to support the drug discovery platform.
- Business combination with Exscientia is advancing towards close, with a special shareholder meeting on November 12, 2024.
Headline financials
Revenue & EPS history
Recursion Pharmaceuticals · Revenue · Quarterly
$26.1M
Revenue by segment
Recursion Pharmaceuticals · $1 total across 1 segment · Q2 2023
- Grant Revenue$1—100.0%
Forward guidance
Recursion expects to host an Update Call around the date of the scheme of arrangement which is expected to be Nov 20, 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-3.1%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+7.2%
Avg return
30 days after
32%
8 / 25 earnings
Positive
+11.6%
Q1 2023
Best reaction
-16.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | -3.3% | -1.8% | |
| Q4 2025 | +6.5% | +2.8% | -16.7% | |
| Q3 2025 | -0.6% | -9.8% | -5.8% | |
| Q1 2025 | -16.5% | -24.0% | -13.9% | |
| Q4 2024 | -12.3% | -16.9% | -29.6% | |
| Q3 2024 | +1.6% | +15.0% | +17.4% | |
| Q2 2024 | -1.3% | +2.7% | -7.1% | |
| Q1 2024 | +0.1% | +17.0% | -0.9% | |
| Q4 2023 | -12.3% | -13.2% | -32.5% | |
| Q3 2023 | -3.0% | +14.7% | +35.0% | |
| Q2 2023 | -0.5% | -13.2% | -24.2% | |
| Q1 2023 | +11.6% | +2.5% | +75.8% | |
| Q4 2022 | +7.1% | +11.4% | -11.3% | |
| Q3 2022 | +8.9% | +32.8% | -0.6% | |
| Q2 2022 | +4.4% | +27.4% | +35.8% | |
| Q1 2022 | -9.4% | +1.4% | +34.4% | |
| Q4 2019 | -0.7% | -1.7% | -14.2% | |
| Q4 2021 | -0.7% | -1.7% | -14.2% | |
| Q3 2020 | -9.1% | -4.3% | -3.2% | |
| Q3 2021 | -9.1% | -4.3% | -3.2% | |
| Q2 2020 | -10.8% | -17.2% | +23.1% | |
| Q2 2021 | -10.8% | -17.2% | +23.1% | |
| Q1 2020 | -7.1% | -3.6% | +37.8% | |
| Q1 2021 | -7.1% | -3.6% | +37.8% | |
| Q4 2020 | -7.1% | -3.6% | +37.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro